» Articles » PMID: 21489305

Discovering Functional Modules by Identifying Recurrent and Mutually Exclusive Mutational Patterns in Tumors

Overview
Publisher Biomed Central
Specialty Genetics
Date 2011 Apr 15
PMID 21489305
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Assays of multiple tumor samples frequently reveal recurrent genomic aberrations, including point mutations and copy-number alterations, that affect individual genes. Analyses that extend beyond single genes are often restricted to examining pathways, interactions and functional modules that are already known.

Methods: We present a method that identifies functional modules without any information other than patterns of recurrent and mutually exclusive aberrations (RME patterns) that arise due to positive selection for key cancer phenotypes. Our algorithm efficiently constructs and searches networks of potential interactions and identifies significant modules (RME modules) by using the algorithmic significance test.

Results: We apply the method to the TCGA collection of 145 glioblastoma samples, resulting in extension of known pathways and discovery of new functional modules. The method predicts a role for EP300 that was previously unknown in glioblastoma. We demonstrate the clinical relevance of these results by validating that expression of EP300 is prognostic, predicting survival independent of age at diagnosis and tumor grade.

Conclusions: We have developed a sensitive, simple, and fast method for automatically detecting functional modules in tumors based solely on patterns of recurrent genomic aberration. Due to its ability to analyze very large amounts of diverse data, we expect it to be increasingly useful when applied to the many tumor panels scheduled to be assayed in the near future.

Citing Articles

Genetic dysregulation of EP300 in cancers in light of cancer epigenome control - targeting of p300-proficient and -deficient cancers.

Gronkowska K, Robaszkiewicz A Mol Ther Oncol. 2024; 32(4):200871.

PMID: 39351073 PMC: 11440307. DOI: 10.1016/j.omton.2024.200871.


Network analysis of driver genes in human cancers.

Patil S, Roberts S, Gebremedhin A Front Bioinform. 2024; 4:1365200.

PMID: 39040139 PMC: 11260686. DOI: 10.3389/fbinf.2024.1365200.


A latent variable model for evaluating mutual exclusivity and co-occurrence between driver mutations in cancer.

Shuaibi A, Chitra U, Raphael B bioRxiv. 2024; .

PMID: 38712136 PMC: 11071465. DOI: 10.1101/2024.04.24.590995.


TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefits.

Wang Y, Wang J, Fang W, Xiao X, Wang Q, Zhao J Front Immunol. 2023; 14:1151755.

PMID: 37234148 PMC: 10208409. DOI: 10.3389/fimmu.2023.1151755.


SuperDendrix algorithm integrates genetic dependencies and genomic alterations across pathways and cancer types.

Park T, Leiserson M, Klau G, Raphael B Cell Genom. 2022; 2(2).

PMID: 35382456 PMC: 8979493. DOI: 10.1016/j.xgen.2022.100099.


References
1.
Segal E, Friedman N, Koller D, Regev A . A module map showing conditional activity of expression modules in cancer. Nat Genet. 2004; 36(10):1090-8. DOI: 10.1038/ng1434. View

2.
Gabor Miklos G, Maleszka R . Microarray reality checks in the context of a complex disease. Nat Biotechnol. 2004; 22(5):615-21. DOI: 10.1038/nbt965. View

3.
Goldman R, Levy R, Peles E, Yarden Y . Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry. 1990; 29(50):11024-8. DOI: 10.1021/bi00502a002. View

4.
Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

5.
Dai M, Wang P, Boyd A, Kostov G, Athey B, Jones E . Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005; 33(20):e175. PMC: 1283542. DOI: 10.1093/nar/gni179. View